Tarsus Pharmaceuticals
Update in progressTARS (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on eye-care medicines in the United States. Its lead product, XDEMVY, is a lotilaner ophthalmic solution for demodex blepharitis. It sells to specialty pharmacies, distributors, clinics, hospitals, and federal programs. It is developing TP-04 for ocular rosacea and TP-05 for Lyme prevention, plus lotilaner API work, with a China collaboration for TP-03. Based in Irvine, CA.
Company score
- Sentiment
- 0.38
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.29
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.24
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Bobak R. Azamian M.D.
- Founded2016
- Employees370
- Websitetarsusrx.com
Identifiers
- ISINUS87650L1035
- FIGIBBG00RB9BNQ7
- CUSIP87650L103
- CIK0001819790